Linio Biotech’s innovation is an injectable tissue product called Tience® (from the words tissue science). The product is intended for professional use only and it helps skin naturally regenerate itself by accelerating the skin’s natural healing process.
Tience® treatment can be used to repair various skin defects, such as signs of aging or unwanted visible scars. The new funding will help Linio Biotech expand the availability of its Tience® product and treatments. Tience® was launched in Finland in June 2023 and is in the beginning of commercialization in other Nordic countries.
Linio Biotech was founded in 2017 as a spin-off from the University of Tampere by its founding partners Timo Ylikomi, professor of cell biology, and cell biologist and researcher Riina Uusmies. The Tience® products are manufactured in Tampere, Finland.
Tience is a breakthrough innovation that treats skin defects and reverses signs of aging. It is a ready-to-use injectable tissue product that helps skin naturally regenerate itself by accelerating the body’s own healing process. Tience treatments are for skin defects such as unwanted scars, fine lines and wrinkles in aging skin.